Member Connect

Log in

Login to your account

Password *
Remember Me
Monday, 15 September 2014 07:17

Treatment adherence

Rate this item
(2 votes)

A NTM-NET chart review of patients treated for MAC disease in the US, Japan and 5 European countries showed that the percentage of patients who received treatment with the recommended 3-drug macrolide regimen for >6 months differed strongly by country.

While a higher percentage of patients in EU5 (68%) received treatment compared with patients in the United States (53%) and Japan (43%), probably reflecting disease severity at (later!) diagnosis, use of ATS guideline-compliant 3-drug macrolide regimens is limited in all regions, but particularly limited in the continental European countries. Read the full ERS 2014 poster here.

Read 5899 times Last modified on Monday, 15 September 2014 10:17